{"id":"W2612879952","doi":"10.1093/rheumatology/kex174","title":"Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA","year":2017,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"Genentech; Astellas Pharma; Chugai Pharmaceutical; Celltrion; Dermira; Gilead Sciences; Ablynx; UCB Pharma; Zynerba Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Certolizumab pegol; BASDAI; BASFI; Internal medicine; Adverse effect; Placebo; Physical therapy; Axial spondyloarthritis; Ankylosing spondylitis; Arthritis; Etanercept; Rheumatoid arthritis; Sacroiliitis; Psoriatic arthritis; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003536384,0.0005125439,0.001058289,0.0003173381,0.0002523378,0.0004918543,0.000363927,0.0007254065,0.001436433],"category_scores_gemma":[0.001292888,0.0001975075,0.001202606,0.0002785534,0.0003808783,0.0005065005,0.0003788478,0.001034986,0.0002511164],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003041252,"about_ca_system_score_gemma":0.0004779325,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003007514,"about_ca_topic_score_gemma":0.0004036075,"domain_scores_codex":[0.9992009,0.0003891734,0.00008400731,0.00008118286,0.0001366012,0.0001081803],"domain_scores_gemma":[0.9983922,0.0002988031,0.0007517139,0.00009782431,0.0001532741,0.0003061478],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7188355,0.02142658,0.08534212,0.001552516,0.002863005,0.000286341,0.0003329109,0.0020468,0.02833464,0.00008726124,0.0008861736,0.1380062],"study_design_scores_gemma":[0.1085478,0.6819871,0.1991649,0.0000977271,0.001853884,0.0004430338,0.00009861089,0.001364712,0.005154282,0.00009944167,0.001143882,0.00004472255],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9975101,0.001641418,0.0001262776,0.00005239441,0.00001259776,0.0001712949,0.0002189216,0.0000100797,0.0002570034],"genre_scores_gemma":[0.9983305,0.0004018681,0.0002465003,0.00007406844,0.00004161461,0.0001863402,0.0003939392,0.000002080364,0.0003231119],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003536384,"threshold_uncertainty_score":0.01870245,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01707595078920577,"score_gpt":0.2762103777811224,"score_spread":0.2591344269919166,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}